Vivek Subbiah: Prepping to ASCO24 – Super Bowl for oncology

Vivek Subbiah shared on LinkedIn:

“Countdown to ASCO24 Annual meeting is on!
Excited for the biggest cancer research event of the year.

Prepping at Sarah Cannon Research Institute getting a glimpse of the latest and greatest breakthroughs right here in Nashville.

It’s like the Super Bowl for oncology

In the photo: Erika Hamilton,Meredith McKean and Andrew McKenzie!

Who else can’t wait?”

Source: Vivek Subbiah/LinkedIn

Vivek Subbiah is the Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute (USA). He is the former Executive Director of Oncology Research at the MD Anderson Cancer Network and a former Associate Professor in the Department of Investigational Cancer Therapeutics at The University of Texas MD Anderson Cancer Center.

Dr. Vivek Subbiah has served as the principal investigator in over 100 phase I/II trials and co-investigator in over 200 clinical trials and is known for his leadership in several first-in-human and practice-changing studies that directly led to approvals from the FDA, European Medicines Agency, and other agencies across the world. He is an expert in tumor agnostic precision oncology and leads the BRAF and RET tissue agnostic studies to FDA approval.